Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature

Wolfgang Hohenforst-Schmidt
Paul Zarogoulidis
Georgia Pitsiou
Bernd Linsmeier
Drosos Tsavlis

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/pulmonary_articles

Recommended Citation
Hohenforst-Schmidt W, Zarogoulidis P, Pitsiou G, Linsmeier B, Tsavlis D, Kioumis I, Papadaki E, Freitag L, Tsiouda T, Turner JF, Browning R, Simoff M, Sachpekidis N, Tsakiridis K, Zarić B, Yarmus L, Baka S, Stratakis G, and Rittger H. Drug eluting stents for malignant airway obstruction: A critical review of the literature J Cancer 2016; 7(4):377-390.

This Article is brought to you for free and open access by the Pulmonary and Critical Care Medicine at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Pulmonary and Critical Care Medicine Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Authors
Wolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Georgia Pitsiou, Bernd Linsmeier, Drosos Tsavlis, Ioannis Kioumis, Eleni Papadaki, Lutz Freitag, Theodora Tsiouda, J F. Turner, Robert Browning, Michael Simoff, Nikolaos Sachpekidis, Kosmas Tsakiridis, Bojan Zaric, Lonny Yarmus, Sofia Baka, Grigoris Stratakos, and Harald Rittger

This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/pulmonary_articles/62
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature

Wolfgang Hohenforst-Schmidt1, Paul Zarogoulidis2,3, Georgia Pitsiou2, Bernd Linsmeier3, Drosos Tsavlis2, Ioannis Kioumis2, Eleni Papadaki2, Lutz Freitag4, Theodora Tsiouda2, J Francis Turner5, Robert Browning6, Michael Simoff7, Nikolaos Sachpekidis8, Kosmas Tsakiridis8, Bojan Zaric9, Lonny Yarmus10, Sofia Baka11, Grigoris Stratakis12, Harald Ritter1

1. Medical Clinic I, "Fuerth" Hospital, University of Erlangen, Fuerth, Germany.
2. Pulmonary Department-Oncoology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3. Department of General Surgery, Coburg Clinic, Coburg, Germany.
4. Department of Interventional Pneumology, Ruhrlandklinik, University Hospital Essen, University of Essen-Duisburg, Tuencher Weg 40, 45239 Essen, Germany.
5. Division of Interventional Pulmonology & Medical Oncology, Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ.
6. Pulmonary & Critical Care Medicine, Interventional Pulmonology, National Naval Medical Center, Walter Reed Army Medical Center, Bethesda, U.S.A.
7. Bronchoscopy and Interventional Pulmonology, Pulmonary and Critical Care Medicine, Henry Ford Hospital, Wayne State University, School of Medicine, MI, USA.
8. Cardiothoracic Surgery Department, "Saint Luke" Private Hospital, Thessaloniki, Panorama, Greece.
9. Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Oncology, Faculty of Medicine, University of Novi Sad, Serbia.
10. Division of Pulmonary and Critical Care Medicine, Sheikh Zayed Cardiovascular & Critical Care Tower, Baltimore, U.S.A.
11. Oncology Department, "Interbalkan" European Medical Center, Thessaloniki, Greece.
12. 1st Respiratory Medicine Department of National University of Athens, "Sotiria" General Hospital Athens, Greece.

© Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.

Received: 2015.08.20; Accepted: 2015.11.01; Published: 2016.01.13

Abstract

Lung cancer being the most prevalent malignancy in men and the 3rd most frequent in women is still associated with dismal prognosis due to advanced disease at the time of diagnosis. Novel targeted therapies are already on the market and several others are under investigation. However non-specific cytotoxic agents still remain the cornerstone of treatment for many patients. Central airways stenosis or obstruction may often complicate and decrease quality of life and survival of these patients. Interventional pulmonology modalities (mainly debulking and stent placement) can alleviate symptoms related to airways stenosis and improve the quality of life of patients. Mitomycin C and sirolimus have been observed to assist a successful stent placement by reducing granuloma tissue formation. Additionally, these drugs enhance the normal tissue ability against cancer cell infiltration. In this mini review we will concentrate on mitomycin C and sirolimus and their use in stent placement.

Key words: pharmacology, stents.

Introduction

Lung cancer still remains a difficult to treat cancer, since patients are diagnosed at late stage disease due to lack of symptoms.[1] Moreover; lung cancer is the second most lethal cancer after prostate for men and breast for women, with a trend to increase for women in the future.[1] Several medical societies are trying to identify those groups of patients that will benefit from imaging screening with several novel techniques.[2-4] Until now there is no algorithm for early diagnostic approach for lung cancer, and patients are usually investigated if symptoms appear. In the last decade several molecular pathways have been investigated and several novel drugs are already on the market for non-small cell lung cancer (NSCLC).[5-8] Regarding small cell lung cancer (SCLC) we still do not have novel therapies, however;
novel treatment approaches are investigated with the main concept of immunomodulation being the most feasible right now.\cite{9-14} Side effects from non-specific cytotoxic agents are well known and there are several patients that have to postpone their treatment.\cite{15, 16} Apart from the side effects induced by the chemotherapeutic agents, there are several situations where the tumor has infiltrated different parts of the airways and respiratory distress is observed.\cite{17} Several techniques can be used to open a closed central airway and chemotherapy or radiotherapy can be used to preserve the result.\cite{18, 19} Debulking of cancer tissue is usually performed with different types of lasers, electrocautery, argon plasma coagulation (APC) or cryotherapy.\cite{20} (Figures 1-2) In order to keep the airway opened we use additionally stent devices.\cite{20, 21} Ballon dilatation and photodynamic therapy (PDT) are other options with specific indications \cite{22, 23} There is also a classification system for airway stenosis that can be used by medical practitioners.\cite{24} Stents have been used for tracheal and esophageal fistulas.\cite{25, 26} For malignant airway stenosis we usually use self-expanding covered or uncovered stents.\cite{21} In order to keep the good result of debulking cancer tissue we have to choose carefully the right time of debulking with systemic, intratumoral \cite{27,149} (or a combination of both modalities of) chemotherapy and/or radiotherapy. Moreover; it has been observed that different stents (diameter, length, materials) induce different local stress.\cite{28} Furthermore stents induce locally stress to the surrounding tissues. They increase proliferation of granuloma tissue in benign airway stenosis and increase angiogenesis. Cancer tissue which already has increased angiogenesis when more stress is applied locally shows further enhanced tissue formation.\cite{29} Therefore novel cytokine eluting stents are being developed.\cite{30} Furthermore, novel research of stent placement at least for the gastrointestinal tract has indicated that stent placement might induce cancer cell migration.\cite{31} Several drugs have been used as adjuvant local application in order to preserve the airway passage.\cite{30, 32-36} In this review we will focus on the drugs that have been used with stents, their pharmacological activity and future applications. Additionally, we will include studies with data applicable for lung cancer patients.

**Search strategy**

We performed an electronic article search through PubMed, Google Scholar, Medscape and Scopus databases, using combinations of the following keywords: mitomycin c, flouxuridine, sirolimus, stents, lung cancer stents, dumon stents, zotarolimus, rapamycin, 5-fluorouracil, doxycycline, everolimus and pirfenidone. All types of articles (randomised controlled trials, clinical observational cohort studies, review articles, case reports) were included. Selected references from identified articles were searched for further consideration.
Drug Pharmacology

Cisplatin

Cisplatin, is a well-known non-specific chemotherapy drug. It is one of the first member of a class of platinum-containing anti-cancer drugs. These days this group of drugs includes carboplatin, oxaliplatin and lipoplatin. These platinum complexes react in vivo, binding to and causing crosslinking of DNA, which finally induce apoptosis. Cisplatin is usually administered intravenously as short-term infusion in normal saline for treatment. It is used to treat (non-)small cell lung cancer, ovarian cancer, lymphomas, bladder cancer, cervical cancer, and germ cell tumors. Cisplatin has been observed to be particularly effective against testicular cancer; the cure rate was improved from 10% to 85%.[38]

Cisplatin is known to crosslink DNA in several different ways, interfering with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis. Most notable among the changes in DNA are the 1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG) adducts which form nearly 90% of the adducts and the less common 1,2-intrastrand d(ApG) adducts. 1,3-intrastrand d(GpXpG) adducts occur but are readily excised by the nucleotide excision repair (NER). Cisplatin has no alkyl group unable to carry out alkylating reactions. However, it is correctly classified as alkylating-like.[39, 40] Of note is the fact that different chemotherapeutic especially alkylating agents (like cyclophosphamide) play a specific role as causative for initiation / aggravation of (underlying) pulmonary hypertension in cancer patients during specific cancer treatment.[27] Such a (by chemotherapy) induced pulmonary hypertension is often classified as pulmonary veno-occlusive disease (PVOD) which resembles in many features a typical pulmonary arterial hypertension but is accompanied with a much worse prognosis in comparison to e.g. an idiopathic pulmonary arterial hypertension. Furthermore the diagnosis of induced PVOD is even more difficult when other hemodynamic comorbidities like left heart disease is already existing on chemotherapy initiation. It is worth mentioning that the establishment of the diagnosis of PVOD itself is very difficult and many times only possible post-mortally. In regards to real-life scenarios with underlying hemodynamic relevant comorbidities it is one of the most complex diagnosis in medicine in human beings alive. Therefore we believe that this diagnosis may be underscored in cancer patients and could be a part of the explanation for the still worse prognosis in many solid cancers especially under treatment despite new, very expensive targeted therapies. It has to be mentioned that any reduction of cardiac output will increase the interstitial fluid pressure intratumorally which is linked to a worse efficacy of any cancer treatment.

Cisplatin resistance

Cisplatin combination chemotherapy is the cornerstone treatment of many cancers. However; many cancer patients will eventually relapse with cisplatin-resistant disease. Mechanisms regarding the cisplatin resistance have been proposed including changes in cellular uptake and efflux of the drug, increased detoxification of the drug, inhibition of apoptosis and increased DNA repair.[41, 42] Oxaliplatin is active in highly cisplatin-resistant cancer cells in the laboratory but there is little evidence for its activity in the clinical treatment of patients with cisplatin-resistant cancer. The drug paclitaxel may be useful in the treatment of cisplatin-resistant cancer; the mechanism for this activity is yet unknown.[43] In regards to hemodynamic properties of paclitaxel it is
of interest that this drug can influence the altitude of life limiting pulmonary hypertension positively via the Forkhead box O (FoxO) transcription factors which are key regulators of cellular proliferation. Using intravenous or inhaled paclitaxel will lead to pharmacological reconstitution of FoxO1 transcription factor activity in pulmonary artery smooth muscle cells (PASMCs) which serves as a potential treatment option for pulmonary hypertension.[44] This detail my be of interest when discussing chemotherapy options in cancer patients with severe pulmonary hypertension beside cancer diagnosis especially in the situation of no or minor response to first line cisplatin.

**Fluorouracil**

Fluorouracil is a pyrimidine analog drug which is used in the treatment of cancer. It is a suicide inhibitor and works through irreversible inhibition of thymidylate synthase. This drug is an antimetabolite. 5-Fluorouracil acts primarily as a thymidylate synthase (TS) inhibitor. Its main action is to block the synthesis of the pyrimidine thymidine which is a nucleoside required for DNA replication. Thymidylate synthase methylates deoxyuridine monophosphate (dUMP) in order to synthesize thymidine monophosphate (dTMP). The administration of 5-FU induces cell death via thymineless death.[45] Calcium folinate stabilises the 5-FU-TS complex and enhances 5-FU's cytotoxicity.[46] There is very little difference between the minimum effective dose and maximum tolerated dose of 5-FU, and it has been observed that the drug exhibits individual pharmacokinetic variability.[47-49] Therefore, an identical dose of 5-FU may result in different therapeutic response between patients.[48] It has been observed that both overdosing and underdosing are of concern with 5-FU. Moreover, the majority of colorectal cancer patients treated with 5-FU are underdosed based on today’s dosing standard, body surface area (BSA).[50-53] The limitations of BSA-based dosing is an issue for many physicians as they cannot accurately titer the dosage of 5-FU for the majority of individual patients, which results in sub-optimal treatment efficacy or excessive toxicity.[51, 52]

The dihydropyrimidine dehydrogenase (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes 5-fluorouracil, tegafur and capecitabine.[54] Moreover, genetic variations within the DPD gene (DPYD) can lead to reduced or absent dihydropyrimidine dehydrogenase activity, and individuals who are heterozygous or homozygous for these variations may have partial or complete DPD deficiency. It is estimated that about 0.2% of individuals have complete dihydropyrimidine dehydrogenase deficiency.[54, 55] Those patients with partial or complete dihydropyrimidine dehydrogenase deficiency have increased risk of severe or even fatal drug toxicities when treated with fluoropyrimidines; such as; neurotoxicity, myelosuppression.[55, 56]

At least two studies have found significant relationships between concentrations of 5-FU in blood plasma and both desirable or undesirable effects on patients. [52, 56] Further evaluation of the drug is based on the concentration of 5-FU in plasma that can increase desirable outcomes while minimizing negative side effects of 5-FU therapy.[52, 56] Towards this direction a blood test has been created and is being used in some centers as My5-FU test.[53]

**Flouxuridine**

Flouxuridine is an antimetabolite. The drug is mostly used in the treatment of colorectal cancer. Flouxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.

**Mitomycin C**

The mitomycins are a family of aziridine-containing natural products isolated from *Streptomyces caespitosus* or *Streptomyces lavendulae*. Mitomycin C (MTC, an antibiotic), finds use as a chemotherapeutic agent by virtue of its antitumour activity. It is applied intravenously to treat upper gastrointestinal cancers (e.g. esophageal carcinoma), breast cancers and anal cancers, moreover; in bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. The usual adverse effects are lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas, like superficial cancers, particularly bladder cancers and intra-peritoneal tumours. It is now well known that a single instillation of this agent within 6 hours on bladder tumor resection can prevent recurrence. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation followed by two N-alkylations. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5’-CpG-3’. [57] Potential bis-alkylating heterocyclic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation.[58] Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.[59] In the study by Li Y. et al. [60] a novel combination of PEGylated phytosomes with mitomycin C has been constructed in order to enhance the efficacy of mitomycin C. PEG complex
has been observed in other studies that induces a "stealth" activity for several chemotherapeutic substances and in this way it produces a release effect for many cytotoxic drugs.[61, 62] In the study by Moiseyenko VM. et al. [63] it was observed that heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation benefited from the administration of mitomycin C. This study provides evidence that several molecular pathways of NSCLC should be investigated along with the local administration of mitomycin C (MTC). In regards to hemodynamic properties of this drug (especially in comparison to the above mentioned details for cisplatin and paclitaxel) it is of interest that MTC intravenous therapy is a potent inducer of PVOD in humans and for intraperitoneal MTC therapy in rats.[64] Amifostine prevents MTC-induced PVOD in rats and should be tested as a preventive therapy for MTC-induced PVOD in humans.

**Special Reference to**

**Pirfenidone**

Pirfenidone is an anti-fibrotic drug which is currently used in the treatment of idiopathic pulmonary fibrosis (IPF). It is known to reduce lung fibrosis through downregulation of the production of growth factors and procollagens I and II. Several studies have established its antifibrotic and anti-inflammatory properties in vitro systems and animal models of fibrosis.[65] A number of cell-based studies have shown that pirfenidone reduces fibroblast proliferation,[66-69] inhibits tumor Growth Factor-β (TNF-β) stimulated collagen production[70] and reduces the production of fibrogenic mediators such as TGF-β.[68] The drug has also shown to reduce production of inflammatory mediators such as tumor growth factor-α (TNF-α) and interleukin 1β (IL-1β) in both cultured cells and isolated human peripheral blood mononuclear cells.[71-74] These activities are consistent with the broader antifibrotic and anti-inflammatory activities observed in animal models of fibrosis and in vitro.[66, 69]

**Everolimus**

Everolimus is known to be a derivative of sirolimus and is considered an inhibitor of mammalian target of rapamycin (mTOR). It is used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumors. Much research has also been conducted on everolimus and other mTOR inhibitors as a possible targeted therapy for use in several types of cancers. Like the others mTOR inhibitors its effect is solely on the mTORC1 protein complex and not on the mTORC2 complex. This function leads to a hyper-activation of the kinase AKT via inhibition on the mTORC1 negative feedback loop while not inhibiting the mTORC2 positive feedback to AKT. This AKT elevation can lead to longer survival in some cell types. Based on this activity everolimus has an important effect on cell growth, cell proliferation and cell survival. It has been observed that mTORC1 action is modulated by several mitogens, growth factors and nutrients.

The two genes TSC1 and TSC2 (which are the genes involved in tuberous sclerosis disease) act as tumour suppressor genes by regulating mTORC1 activity. Therefore the loss or inactivation of one of these genes leads to the activation of mTORC1.[75]

Everolimus binds to its protein receptor FKBP12, which directly interacts with mTORC1 inhibiting its downstream signaling. As a consequence, mRNAs that codify proteins implicated in the cell cycle inhibit tumour growth.[75]

Recent trials have indicated that adding Afinitor (everolimus) to exemestane therapy against advanced breast cancer can significantly improve progression-free survival compared with exemestane therapy alone.[76, 77] However, everolimus increased mortality in cancer patients in some studies.[77-79]

Furthermore, there are two studies that show a different sensitivity to everolimus between patients depending on their genome.[79, 80] In a Phase II clinical trial done in patients with advanced metastatic bladder carcinoma (NCT00805129)[80] they found one person that positively responded to everolimus treatment for 26 months. A genetic sequence was performed for this patient. It was discovered that mutations in TSC1 lead to an increase in recurrence and to an increase in the response time to everolimus. Therefore, it has been determined that everolimus is more efficient in those patients that present somatic mutations in TSC1.[81]

**Zotarolimus**

Zotarolimus is an immunosuppressant and is considered a semi-synthetic derivative of rapamycin. It was primarily designed for use in stents with phosphorylcholine as a carrier. It was observed that coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. However, complications have been observed with stent use, such as the development of thrombosis which impedes the efficiency of coronary stents. Moreover; haemorrhagic and restenosis complications are additional problems that can be observed. Therefore drug-eluting stents have been developed. Stents are bound by a membrane consisting of polymers which releases zotarolimus slowly and its derivatives into the surrounding
tissues. Zotarolimus is an analog made by substituting a tetratetrazole ring in place of the native hydroxyl group at position 42 in rapamycin. The compound is extremely lipophilic, and therefore has limited water solubility. The poor water solubility prevents rapid release into the circulation (for coronary stents) since elution of drug from the stent will be partly dissolusion rate-limited. The slow rate of release and subsequent diffusion of the molecule facilitates the maintenance of therapeutic drug levels eluting from the stent. However; the surrounding tissue has to be considered too. Moreover; its lipophilic property induces crossing cell membranes to inhibit neointimal proliferation of target tissue. Zotarolimus is the most lipophilic of all drug eluting stents (DES) drugs. [82]

**Sirolimus**

Sirolimus (also known as rapamycin) is a chemical that was discovered as a product of bacteria. Sirolimus, was originally developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties. It has been shown to prolong the life of mice and might also be useful in the treatment of certain cancers. [83] Sirolimus is not a calcineurin inhibitor, but it has a similar suppressive effect on the immune system. Sirolimus inhibits interleukin-2 (IL-2) and other cytokines receptor-dependent signal transduction mechanisms, via action on mTOR, and thereby blocks the activation of T and B cells. It is known that tacrolimus and cyclosporine inhibit the secretion of IL-2, by inhibiting calcineurin. Sirolimus binds to the cytosolic protein FK-binding protein 12 (FKBP12) like tacrolimus. Unlike the tacrolimus-FKBP12 complex, which inhibits calcineurin (PP2B), the sirolimus-FKBP12 complex inhibits the mTOR (mechanistic (formerly mammalian) target of Rapamycin. Rapamycin directly binds to mTOR Complex 1 (mTORC1). mTOR has also been called FRAP (FKBP-rapamycin-associated protein), RAP1, RAFT (rapamycin and FKBP target). Sirolimus binds to FKBP12-sirolimus complex and inhibits Tor1 and Tor2. [84-86] There have been numerous studies with sirolimus-eluting stents used for coronary disease. [87-91] Sirolimus eluting stents have demonstrated that they can inhibit neointimal proliferation when applied next to bare metal stents. [87, 92, 93] Several groups have investigated different combinations of sirolimus and sustain release drugs in order to prolong the positive effect of the stent. [88, 89, 94, 95] Several imaging methods have been also applied in order to evaluate sirolimus stent implantation in the coronary vessels. [91, 96, 97] In the study by Habib et. al. [98] it was observed that metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors. Metformin could therefore be administered as an adjuvant treatment for these patents or added in the eluting solution. The administration of granulocyte colony-stimulating factor has been observed to attenuate endothelial dysfunction after sirolimus eluting stent implantation. [99] In the study by Erdim et. al. [100] and Tarantini et. al. [101] there was a difference observed between paclitaxel eluting stents and sirolimus eluting stents. The same was true when sirolimus and paclitaxel eluting stents were compared to bare metal stents. [102]

**Paclitaxel**

Paclitaxel is used to treat a number of cancers such as; ovarian cancer, breast cancer, lung cancer and pancreatic cancer. Paclitaxel and docetaxel represent the taxane family of drugs. Paclitaxel's mechanism of action involves interference with the normal breakdown of microtubules during cell division. Its common side effects include: muscle and joint pains, hair loss, and diarrhea. Anaemia and infections can occur and can be potentially serious. It should not be used during pregnancy as it often results in problems in the infant. Paclitaxel is used as an antiproliferative agent for the prevention of restenosis (recurring narrowing) of coronary and peripheral stents; locally delivered to the artery wall. It has been observed that paclitaxel coating limits the growth of neointima (scar tissue) within stents. [103] It is known that paclitaxel targets tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Consequently chromosomes are unable to achieve a metaphase spindle configuration. This function blocks progression of mitosis, and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G-phase of the cell cycle without cell division. It has been observed that the ability of paclitaxel to inhibit spindle function is generally attributed to its suppression of microtubule dynamics. Moreover; in vitro studies it has been observed that at higher therapeutic concentrations, paclitaxel appears to suppress microtubule detachment from centrosomes. This process occurs during mitosis. Paclitaxel binds to beta-tubulin subunits of microtubules. [104-108] Paclitaxel eluting stents have been used for airway bypass [109] and for coronary vessel implantation. [100-102, 110-114] Paclitaxel solution has been also conjugated with a carrier in order to produce a sustain drug release effect. [115]

**Doxycycline**

Doxycycline is a broad-spectrum antibiotic of the
tetracycline class that is useful for the treatment of many infections. Doxycycline–metal ion complexes are unstable at acid pH, therefore more doxycycline enters the duodenum for absorption while other earlier tetracycline compounds are released in the upper gastrointestinal tract. Moreover; it was mentioned that food has less effect on absorption than on absorption of earlier drugs with doxycycline serum concentrations being reduced by about 20% by test meals compared with 50% for tetracycline.[116] Expired tetracyclines or tetracyclines allowed to stand at a pH less than 2 are reported to be nephrotoxic due to the formation of a degradation product, such as the hydro-4-epitetracycline which induces the Fanconi syndrome. It is known for doxycycline that the absence of a hydroxyl group in C-6 prevents the formation of this nephrotoxic compound. Tetracyclines and doxycycline itself have to be taken with precaution by patients with kidney injury, as they can worsen azotemia due to catabolic effects.[117] In the study by Huvenne W. et al. [36] it was observed that doxycycline-releasing stents improved postoperative healing after functional endoscopic sinus surgery.

**Sirolimus vs. Everolimus**

In the study by Gao R. et al. [94] novel abluminal groove-filled biodegradable polymer sirolimus eluting stent was investigated versus a durable polymer everolimus-eluting stent: None of the two stents presented positive results after 12 months follow up and none was observed to be superior. Regarding the novel abluminal groove-filled biodegradable polymer sirolimus eluting stent the authors stated that the stent was not inferior to the everolimus stent. The stents were found to be effective mainly for the first nine months. In the study by Smits P. C. et al. [118] abluminal biodegradable polymer biolimus-eluting stents were tested versus durable polymer everolimus stents: This time the biolimus stents were found to be as effective as the everolimus stents. In the study by Harjai K. J. et al. [110] it was observed that everolimus eluting stents were more efficient when compared to sirolimus and paclitaxel eluting stents at least for 3 months of follow up. Again in the study by Park K. W. et al. [119] Kitabata H. et al. [120], Moreno R. et al. [121], Kozuma K. et al. [122] and Ko Y-G. et al. [97] everolimus eluting stents were found to be superior when compared to sirolimus eluting stents.

**Zotarolimus vs. Everolimus**

In the study by Tandjung K. et al. [123] no difference was observed between the zotarolimus and everolimus stents in terms of safety and efficiency. However; in the study by Kim S. et al. [124] although zotarolimus had rapid neointimal healing at 3 months, the zotarolimus stents had a slightly better vascular healing profile at long term 12 months. In the study by Park K. W. et al. [125] both zotarolimus and everolimus stents showed the same safety and efficiency profile after 1 year follow-up.

**Zotarolimus vs. Paclitaxel**

In the study by Xu B. et al. [126] it was observed that zotarolimus stents were more efficient when compared to paclitaxel eluting stents within 12 months of follow up.

**Sirolimus vs. Zotarolimus**

In the study by Van den Branden B. et al. [127] sirolimus eluting stents were found to have higher efficiency than zotarolimus stents.

**Stent Studies for the respiratory tract**

**Cisplatin**

In the study by Chao YK et al. [35] biodegradable stents made of polycaprolactone were fabricated by a laboratory-made, microinjection molding machine. Initially, in vitro mechanical strength of the stents was compared with the strength of Ultraflex SEMSs. Poly-lactide-polyglycolide copolymer and cisplatin were coated onto the surfaces of the stents. Elution method and high-performance liquid chromatography (HPLC) analysis were used to examine the in vitro cisplatin release characteristics. In vivo, the stents were surgically implanted into the cervical trachea of white rabbits. Bronchoscopic examination was performed weekly and Cisplatin concentrations in trachea, lung, and blood were analyzed by HPLC. Histologic examination was also performed. The biodegradable stent exhibited mechanical strength comparable to the strength of Ultraflex SEMSs and provided a steady release of cisplatin for 4 weeks in vitro. The in vivo study showed sustained cisplatin levels in rabbit trachea for 5 weeks with a minimum drug level in blood. Histologic examination showed an intact ciliated epithelium and marked leukocyte infiltration in the submucosa of the stented area.

**Mitomycin C**

In the study by Choong C. K. et al. [128] mitomycin C (MTC) was administered locally after stent placement for airway bypass and blocked granuloma tissue formation for up to a week. In the study by Coppit G. et al. [129] MTC failed to affect the acute inflammatory response, perhaps secondary to the robust inflammatory reaction created by combining a single-stage laryngotraceal reconstruction (SSLTR) with the local circumferential trauma induced by the Palmaz stent. This may have reduced the beneficial effects of the MTC in this study. However; incorpora-
tion of the auricular cartilage graft the stent was improved, contributing again to improved airway stability. The mechanism of this action is not yet understood, as MTC is considered a potent fibroblast inhibitor and not a promoter of neochondrogenesis. It is possible that this is an effect of MTC not previously described. In the study by Sztano B. et. al. [130] mitomycin C prolonged fibrotic tissue formation for almost 6 weeks in a young boy. On the other hand in the study by Uzomefuna V. et. al. [131] again it did not present a positive antiproliferative effect, however; the authors provide data where the effect might be associated with the patients’ age. In the study by Carter J. M. et. al. [132] the positive application of MTC was observed with fewer days of hospitalization. In another study by Kim H. et. al. [133] investigating again the effect of MTC application in congenital choanal atresia as in the study by Carter J. M. et. al. [132] no positive effect was observed in this group. In the study by Cardoso P.F.G. et.al. [109] paclitaxel eluting stents were used for airway bypass. Initial results indicated reduction of hyperinflation and improved pulmonary function and dyspnea. In the study by Choong C.K. et. al. [134] in an animal model prolongation of patency was observed. However; in the study by Shah P.L. et. al. [135] no benefit was observed from these stents for homogenous emphysema. Although a previous study by the same group implicated that these patients might benefit from these stents,[136] In the study by Zhu G. H. et. al. [137] bioabsorbable tubular stents eluting MTC (tracheal) were created and they were found to be superior to silicone stents. This study is very important because it provides data regarding the importance of the stent design in mucus trapping. The authors propose a stent design along with a drug eluting carrier, however; further investigation is needed for the stent design.

**Doxycycline**

In the study by Huvenne W. et. al. [36] doxycycline drug eluting stents were designed and applied for sinus surgery. It was observed that matrix metalloproteinase-(MMP-9) levels were lower along with bacterial colonization and additionally short time healing was observed.

**Carriers designed for coronary, airway and gastrointestinal stents**

In the study by Bang S. et. al. [138] paclitaxel-eluting membranes were designed in order to release paclitaxel: Positive results have been observed for more than 15 days after implantation. In the study by Qiu H. et. al. [88] sirolimus bioabsorable poly-L-lactic acid stents were designed and were effective up to 28 days. In the study by Deng J. et. al. [89] a nanoporous CREG-sirolimus eluting stent was designed with positive effects between 2-4 weeks. In the study by Christiansen E. H. et. al. [139] a biolimus-eluting biodegradable polymer-coated stent was compared to durable polymer-coated sirolimus-eluting stent, however; after 1 year the results did not indicate a superiority of these novel stents. In the study by Gao R. et. al. [94] novel abluminal groove-filled biodegradable polymer sirolimus eluting stent was investigated versus a durable polymer everolimus-eluting stent: None of the two stents presented positive results after 12 months follow up and none was observed to be superior from one another. In the study by Huvenne W. et. al. [36] a doxycycline eluting stent was created from copolymer blocks. It was observed that matrix metalloproteinase-(MMP-9) levels were lower along with bacterial colonization and additionally short time healing was observed. In the study by Chao Y. et. al. [35] polylactide-polyglycolide copolymer-cisplatin stents were designed and a sustainable release was observed for up to 5 weeks. In the study by Lemos P. et. al. [140] using polymer-free phospholipid encapsulated sirolimus nanocarriers stents the drug transfer was feasible to all layers of the vessel wall, achieving high tissue concentration that persisted days after the application. In the study by Seo J-B. et. al. [113] two different types of paclitaxel eluting stents were investigated: The polymer polysulfone (Coroflex) and polymer “Translute” (Taxus). The Taxus stent was observed to be superior to the Coroflex within a 9 month follow up.

**Discussion**

The inherent growth inhibitory properties of many anti-cancer agents make these drugs ideal candidates for the prevention of restenosis. However, these same properties are often associated with local cytotoxicity such as; fistulas. Therefore a multimodal approach is necessary either with debulking and then stent placement or radiotherapy when appropriate. Performance status, comorbidities, disease extend and anatomical malformations of the patient should be considered.

Preparation is necessary in many cases as airway malformation is observed and therefore 3 dimensional investigation has been proposed.[141] In the study by Ratnovsky A. et. al. [28] the stress of different materials were investigated and the authors proposed a patient-specific trachea model evaluation before stenting the patient. The method of stent application/stress, different material and different tissue (benign/malignant) could probably be assessed one day for each patient before application in order to avoid
adverse effects. Since MTC is an antitumour drug that is used in both benign and malignant tissue formation after stent placement, we suggest that other cytotoxic agents with or without carrier that modulate the release of the drug locally should be investigated.\[57\]

Regarding pirfenidone, we cannot propose further studies when we have tissue formation around the edge of a stent if the underlying disease is cancer, however; it would be interesting to design pirfenidone eluting stents for benign obstructions. In the study by Barone-Rochette G. et al. \[142\] data are presented where current technology of drug eluting stents is cost effective and therefore novel stents should be encouraged. An issue to be investigated is whether we should provide the patients with an adjuvant therapy when implanting an airway stent. There is the case of the immunosuppressant rapamycin which was the basis for the development of zotarolimus by Johnson and Johnson. Rapamycin was originally approved for the prevention of renal transplant rejection in 1999. There is evidence for coronary stents that when metformin is administered impairment of vascular endothelial recovery is observed. More studies should be performed towards this direction. Another issue is the adverse effects of the drugs that are conjugated with the stent. There is a case reported where a zotarolimus eluting stent induced hypersensitivity pneumonitis.\[143\] In the study by Iwata Y. et al. \[99\] granulocyte colony-stimulating factor was administered and it was observed that endothelial dysfunction was attenuated after sirolimus eluting stents implantation. Again in the study by Rhew S. H. et al. \[144\] repeated catastrophic multi-vessel coronary spasm was observed after zotarolimus-eluting stent. In the study by Zhu G. H. et al. \[137\] bioabsorbable tubular tracheal stents eluting MTC were created and found to be superior to silicone stents. This study is very important because it provides data regarding the importance of the stent design in mucus trapping. The authors propose a stent design along with a drug eluting carrier, however; further investigation is needed for the stent design. 5-fluorouracil (5-FU) nitinol stents have been used for the gastrointestinal tract, and could be investigated for the respiratory tract.\[145\] There are currently novel methods for evaluating the concentration of paclitaxel and 5-FU simultaneously \[146\], moreover; novel amphiphilic copolymers have been designed to control the drug release such as; 5-FU.\[146-148\] (Figure 3, Tables 1-2)

In our mini review we investigate the current knowledge from the coronary drug eluting stents and we present also a comparison between the different materials. We are trying to create a bridge between this knowledge and the data that we obtained from eluting airway stent techniques. There has not been much effort towards stents for lung cancer patients. The main reason is that patients usually have a low performance status when stents are applied usually as palliative treatment. Moreover; interventional pulmonology has many tools for rapid local control. However; a long term local therapy through airway stents for these patients is welcomed. Going through the literature we believe that an ideal airway stent should (1) possess sufficient strength to perform its mechanical function, (2) be biocompatible so that the material breakdown process will not cause any tissue irritation, (3) be biodegradable (no need for removal after serving its purpose), and/or (4) provide effective pharmaceuticals for a sustained period of time. Before stent placement we propose investigation of the airways with computertomography scans and bronchoscopy in order to choose the best stent design and make the appropriate intervention. Finally, the type of lung cancer should direct us to choose the appropriate drug in order to invent drug eluting stents. Agents effective against specific types of lung cancers have been found, such as permetrexed for adenocarcinoma or TKIs for EGFR or ALK positive patients.

| Author          | Subject | Drug                  | Result                                      | Ref  |
|-----------------|---------|-----------------------|---------------------------------------------|------|
| Chao Y.K. et al.| animals | Cisplatin with carrier| 5 week with apoptosis                       | 35   |
| Choong C.K. et al.| animals | Mitomycin C           | 1 week                                      | 129  |
| Coppi G. et al.| animals | Mitomycin C           | No effect                                   | 130  |
| Szanto B.et. al.| human   | Mitomycin C           | 6 weeks                                     | 131  |
| Uzomefuna V. et al.| human | Mitomycin C           | No effect                                   | 132  |
| Carter J. M. et al.| human | Mitomycin C           | Less hospitalisation days                   | 133  |
| Kim H. et. al.| human   | Mitomycin C           | No effect                                   | 134  |
| Cardoso F.G.P. et al.| human | Paclitaxel           | Positive effect (emphysema application)     | 110  |
| Choong C. K. et al.| animal | Paclitaxel           | Prolongation of patency                     | 135  |
| Shah P.L.et. al.| human   | Paclitaxel           | No benefit, however; safe                   | 136  |
| Huvenne W. et al.| human   | Doxycycline         | Shorter healing time, less bacterial colonization, lower MMP-9 levels | 36   |

Table 1. Stent studies (In the result section the referenced time indicates the time where the first positive results were observed.)
Table 2. Carriers designed for coronary and airway stents.

- Paclitaxel eluting stents
- Sirolimus bioabsorbable poly-L-lactic acid
- Nanoporous CREGES (Sirolimus)
- Biolimus-eluting biodegradable polymer-coated stent
- Novel abluminal groove-filled biodegradable polymer sirolimus eluting stent
- Doxycycline eluting stent was created from copolymer blocks
- Poly(lactide-co-glycolide) copolymer-cisplatin
- Polymer-free phospholipid encapsulated sirolimus nanocarriers
- Bioabsorbable tubular stents
- Amphiphilic poly-(caprolactone)-poly(ethylene glycol)-poly-(caprolactone) (PCL-PEG-PCL) copolymers
- trilayered Poly-(caprolactone) (PCL)-based film with a coating layer (CL), a drug-storing layer (DSL)

Figure 3. Drug eluting stents algorithm.

Conflict of Interest
None to declare.

References
1. Rosso T, Bertuccio P, La Vecchia C, Negri E, Malvezzi M. Cancer mortality trend analysis in Italy, 1980-2010, and predictions for 2015. Tumori. 2015; 0: 0. doi:10.5301/tj.5000352.
2. Chin J, Syrek Jensen T, Ashby L, Hermansen J, Hutter JD, Conway PH. Screening for lung cancer with low-dose CT--translating science into Medicare coverage policy. The New England journal of medicine. 2013; 372: 2083-5. doi:10.1056/NEJMp1302598.
3. Omura Y, Lu D, O’Young B, Jones M, Nihzane A, Durvi H, et al. New non-invasive safe, quick, economical method of detecting various cancers was found using QRS complex or rising part of T-wave of recorded ECGs. Cancers can be screened along with their biochemical parameters & therapeutic effects of any cancer treatments can be evaluated using recorded ECGs of the same individual. Acupuncture & electro-therapeutics research. 2015; 40: 1-15.
4. Gao L, Xie E, Yu T, Chen D, Zhang L, Zhang B, et al. Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with undetermined solitary pulmonary nodules. Journal of thoracic disease. 2015; 7: 422-32. doi:10.3978/j.issn.2072-1439.2015.01.24.
5. Zaric B, Stojisic V, Tepavac A, Sarcev T, Zarogoulidis P, Darwiche K, et al. Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC). Journal of thoracic disease. 2015; 7: S371-7. doi:10.3978/j.issn.2072-1439.2013.05.16.
6. Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, et al. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. Journal of Cancer. 2013; 4: 736-54. doi:10.7150/jca.7734.
7. Lampaki S, Lazaridis G, Zarogoulidis K, Kiousis I, Papaiwannou A, Tsirgogianni K, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. Journal of Cancer. 2015; 6: 568-74. doi:10.7150/jca.11893.
8. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). Journal of thoracic disease. 2013; 5 Suppl 4: S389-96. doi:10.3978/j.issn.2072-1439.2013.07.10.
9. Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Kristofordis M, Liaka A, et al. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC? Journal of Cancer. 2015; 6: 360-6. doi:10.7150/jca.11308.
10. Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerassimou G, Zarogoulidis P, Sapardanis I, et al. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung cancer. 2012; 76: 84-8. doi:10.1016/j.lungcan.2011.09.014.
11. Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, et al. Gene Expression Analysis of the 265 Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. Journal of Cancer. 2014; 5: 646-54. doi:10.7150/jca.9955.
12. Zarogoulidis K, Ziogas E, Boutsikou E, Zarogoulidis P, Darwiche K, Kontakiotis T, et al. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. Drug design, development and therapy. 2013; 7: 611-7. doi:10.2147/DDDT.S43184.
13. Zarogoulidis K, Ziogas E, Papagiannis A, Charitopoulos K, Dimitriadis K, Economides D, et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung cancer. 1996; 15: 197-205.
14. Zarogoulidis K, Latissios D, Porpodis K, Zarogoulidis P, Darwiche K, Antoniou N, et al. New dilemmas in small-cell lung cancer TNM clinical staging. Oncotargets and therapy. 2013; 6: 539-47. doi:10.2147/OTT.S44201.
15. Zarogoulidou V, Panagopoulou E, Papakosta D, Petridis D, Porpodis K, Zarogoulidis K, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. Journal of thoracic disease. 2015; 7: S12-9. doi:10.3978/j.issn.2072-1439.2015.01.37.
16. Lithoxopoulou H, Zarogoulidis K, Rostantzopoulou S, Eleftheriadou E, Zarogoulidis P, Huang H, et al. Monitoring changes in quality of life in patients...
with lung cancer by using specialised questionnaires: implications for clinical practice. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2014; 22: 2177-83.

17. Freitag L, Darwich K. Endoscopic treatment of tracheal stenosis. Thoracic surgery clinics. 2014; 24: 27-40. doi:10.1016/j.tsc.2013.10.003.

18. Zarogoulidis P, Darwich K, Tsakiridis K, Tsichler H, Yarns M, Zarogoulidis K, et al. Learning from the Cardiologic Literature: Stenting Targets the Mitr Valve for Pulmonary Application: A Future Concept for Tracheal Stenosis. Journal of molecular and genetic medicine : an international journal of biomedical research. 2013; 7: 65. doi:10.4172/1747-8682.1000065.

19. Hohenforst-Schmidt W, Linsemeier B, Zarogoulidis P, Freitag L, Darwich K, Browning R, et al. Transtacheal single-point stent fixation in posttraecheomaty tracheomalacia under cone-beam computer tomography guidance by transmural suturing with the Berci needle - a perspective on a new tool to avoid stent-induced tracheal stenosis. Therapeutics and clinical risk management. 2015; 11: 85-37. doi:10.2147/TCRM.S83220.

20. Bolliger CT, Sutedja TG, Strausz J, Freitag L. Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. The European journal of cancer. 2006; 27: 1256-71. doi:10.1016/j.ejca.2006.01.006.

21. Freitag L. Interventional endoscopic treatment. Lung cancer. 2004; 45 Suppl 2: S235-8. doi:10.1016/j.junagang.2004.07.970.

22. Freitag L, Ernst A, Thomas M, Prenzel R, Wahlers B, Mcha HN, et al. Sequential prolonged hyperbaric oxygen therapy (PHTD) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax. 2004; 59: 790-3. doi:10.1136/thx.2003.013599.

23. Freitag L, PDT in early central lung cancer. Thorax. 2007; 62: 374-5. doi:10.1136/thx.2006.058792.

24. Freitag L, Ernst A, Unger M, Kovitz K, Marquette CH. A proposed classification system of central airway stenosis. The European respiratory journal. 2007; 30: 7-12. doi:10.1183/09059186.0003806.

25. Stanatis G, Freitag L; [Tracheoesophageal fistula]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizin. 2011; 82: 148-53. doi:10.1002/ajenh.201019774.

26. Freitag L, Tolkoff E, Steveling H, Donovan TJ, Stamatis G. Management of malignant esophagealtracheal fistulas with airway stenting and double stenting. Chest. 1996; 115: 1150-6.

27. Ranchoux B, Gunther S, Quarrck R, Chaumais MC, Dorfmueller P, Antigny F, et al. Chemotherapy-induced pulmonary hypertension: role of alkyating agents. The American journal of pathology. 2015; 185: 356-71. doi:10.2353/ajpath.2014.10.021.

28. Ratnovsky A, Regev N, Wald S, Kramer M, Naftali S. Mechanical properties of adult and pediatric tracheomalacia under cone-beam computer tomography. Laryngoscope. 2015; 125: E210-5. doi:10.1002/lary.25178.

29. Crino L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. European respiratory review : an official journal of the European Respiratory Society. 2014; 23: 79-91. doi:10.1183/09059180.00008913.

30. Freitag L, Ernst A, Unger M, Kovitz K, Marquette CH. A proposed classification system of central airway stenosis. The European respiratory journal. 2007; 30: 7-12. doi:10.1183/09059186.0003806.

31. Malgras B, Brunelle L, Lo Dico R, El Marjou F, Robine S, Therwath A, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Annals of surgical oncology. 2015. doi:10.1245/s10434-015-4014-5.

32. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chemistry. 2015. doi:10.1007/s00417-015-3068-1.

33. Zheng Z, Touve M, Barnes J, Reich N, Zhang L. Synthesis-enabled probing of ranitidine's role in drug delivery for in vivo application. International journal of nanomedicine. 2012; 7: 1551-72.

34. Freitag L, Darwich K. Ultrasound localization of malignant tracheal stenosis during laser therapy. Journal of biomedical research. 2013; 7: 65. doi:10.4172/1747-0862.1000065.

35. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. Cancer nanomedicine. 2012, Vol. 7 63. Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, et al. Evidence for clinical efficacy of mitomycin C in heavily pretreated patients with head and neck cancer. Journal of cancer. 2008; 20: 334-5. doi:10.1177/20070334.082338.

36. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. International journal of nanomedicine. 2012; 7: 1551-72.

37. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. International journal of nanomedicine. 2012; 7: 1551-72. doi:10.1177/20070334.082338.

38. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. International journal of nanomedicine. 2012; 7: 1551-72. doi:10.1177/20070334.082338.

39. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. International journal of nanomedicine. 2012; 7: 1551-72. doi:10.1177/20070334.082338.

40. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. International journal of nanomedicine. 2012; 7: 1551-72. doi:10.1177/20070334.082338.
pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Medical oncology. 2014; 31: 199. doi:10.1007/s12032-014-0199-x.

64. Perros F, Ganther S, Ranchoux B, Codinas I, Antigny F, Chaumais MC, et al. Mammalian target of rapamycin (mTOR) in diffuse infiltrating large B-cell lymphoma. Blood. 2012; 120: 2398-2403. doi:10.1182/blood-2012-01-396728.
106. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature reviews. Cancer 2004; 4: 235-65. doi:10.1038/nrc1317.

107. Ganguly, A, Yang H, Cabral F. Paclitaxel-dependent cell lines reveal a novel drug-resistance activity in breast cancer. Molecular cancer therapeutics. 2010; 9: 2914-25. doi:10.1158/1535-7163.MCT-10-0552.

108. Lowe J, Li H, Downing KH, Nogales E. Refined structure of alpha-tubulin at 3.5 Å resolution. Journal of molecular biology. 2001; 313: 1045-57. doi:10.1006/jmbi.2001.4777.

109. Cardoso PF, Snell GI, Hopkins P, Sybrecht GW, Stamatis G, Ng AW, et al. Clinical outcome of airway bypass with paclitaxel-eluting stents: early results. The Journal of thoracic and cardiovascular surgery. 2007; 134: 974-81. doi:10.1016/j.jtcvs.2006.07.050. e1-2. doi:10.1016/j.cardio.2006.07.027.

110. Harju KJ, Kondareddy S, Pinskyos B, Harjai N, Orshaw P, Bouja J. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Gufhi Health Off-Label Stent (GHIST) registry. Journal of interventional cardiology. 2013; 26: 153-62. doi:10.1111/j.1531-5507.2013.12016.x.

111. Dave MD, Ansel GM, Jaff MR, Okhi T, Saxon RR, Smouse HB, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. Journal of the American college of cardiology. 2013; 61: 2417-27. doi:10.1016/j.jacc.2013.03.034.

112. Wohrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, et al. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents: 2-year results. The Journal of thoracic and cardiovascular surgery. 2006; 131: 60-4. doi:10.1016/j.jtcvs.2005.07.057.

113. Christensen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, et al. The favorable price evolution between bare metal stents and drug eluting stents: a systematic review and meta-analysis of 11 randomized trials. American heart journal. 2013; 165: 767-83. doi:10.1016/j.ahj.2012.08.007.

114. Shah PL, Hopkinson NS. Bronchoscopic lung volume reduction for emphysema: where next? The European respiratory journal. 2012; 39: 1287-9. doi:10.1183/09031936.02174111.

115. Shah PL, Siebbe DS, Cardoso PF, Ett J, Sybrecht GW, Cooper JD. Design of the exhalate airway stents for emphysema (EASE) trial: an endoscopic procedure for reducing hyperinflation. BMC pulmonary medicine. 2011; 1: 1. doi:10.1186/2040-244x-1-11.

116. Zhu GH, Ng AH, Venkatraman SS, Boey FY, Wei AL, Trasti SL, et al. A novel bioabsorbable drug-eluting tracheal stent. The Laryngoscope. 2012; 122: 2335-49. doi:10.1002/lary.22175.

117. Bang S, Jiang ST, Lee SY, Baek YY, Yoon J, Oh JH, et al. Molecular mechanism of local drug delivery with Paclitaxel-eluting membrahy bilirubin and pancreatic cancer: a new application for an old drug. Gastroenterology research and practice. 2015; 2015: 569891. doi:10.1155/2015/569891.

118. Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Kruel KL, Hansen KN, et al. Sirolimus-eluting vs. polymer-coated sirolimus-eluting stents in unsedected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet. 2013; 381: 661-9. doi:10.1016/S0140-6736(12)61692-X.

119. Lemos PA, Faraouq V, Takamura CK, Gutierrez PS, Virmani R, Kollogod F, et al. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013; 9: 841-3. doi:10.4244/EIJV9I1A21.

120. Miyazaki T, Yamashiki N, Tsuchiya T, Matsumoto K, Takagi K, Nagayasu T. Airway stent insertion simulated with a three-dimensional printed airway model. The Annals of thoracic surgery. 2015; 99: e21-3. doi:10.1016/j.athoracsur.2014.10.021.

121. Barone-Rochette G, Machecourt J, Vanzetto G, Foote A, Quedasa JL, Castelli C, et al. The favorable price evolution between bare metal stents and drug eluting stents increases the cost effectiveness of drug eluting stents. International journal of health economics and policy. 2013; 16: 255-65. doi:10.1016/j.ijhep.2012.06.024.

122. Kim H, Park JH, Chung H, Han DH, Kim DY, Lee CH, et al. Clinical features and surgical outcomes of congenital choanal atresia: factors influencing success from 28-year review in an institute. American journal of otolaryngology. 2012; 33: 308-12. doi:10.1016/j.amjoto.2011.08.010.

123. Choong CK, Pan L, Massetti P, Haddad FJ, Martinez C, Roschek E, et al. Prolongation of patency of airway bypass stents with use of drug-eluting stents. The Journal of thoracic and cardiovascular surgery. 2006; 131: 60-4. doi:10.1016/j.jtcvs.2005.07.056.

124. Shah PL, Hopkinson NS. Bronchoscopic lung volume reduction for emphysema: where next? The European respiratory journal. 2012; 39: 1287-9. doi:10.1183/09031936.02174111.

125. Shah PL, Siebbe DS, Cardoso PF, Ett J, Sybrecht GW, Cooper JD. Design of the exhalate airway stents for emphysema (EASE) trial: an endoscopic procedure for reducing hyperinflation. BMC pulmonary medicine. 2011; 1: 1. doi:10.1186/2040-244x-1-11.

126. Zhu GH, Ng AH, Venkatraman SS, Boey FY, Wei AL, Trasti SL, et al. A novel bioabsorbable drug-eluting tracheal stent. The Laryngoscope. 2012; 122: 2335-49. doi:10.1002/lary.22175.
146. Chen W, Shen Y, Rong H, Lei L, Guo S. Development and application of a validated gradient elution HPLC method for simultaneous determination of 5-fluorouracil and paclitaxel in dissolution samples of 5-fluorouracil/paclitaxel-co-eluting stents. Journal of pharmaceutical and biomedical analysis. 2012; 59: 179-83. doi:10.1016/j.jpba.2011.10.005.

147. Lei L, Liu X, Shen YY, Liu JY, Tang MF, Wang ZM, et al. Zero-order release of 5-fluorouracil from PCL-based films featuring trilayered structures for stent application. European journal of pharmacetics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2011; 78: 49-57. doi:10.1016/j.ejpb.2011.01.003.

148. Lei L, Liu X, Guo S, Tang M, Cheng L, Tian L. 5-Fluorouracil-loaded multilayered films for drug controlled releasing stent application: Drug release, microstructure, and ex vivo permeation behaviors. Journal of controlled release: official journal of the Controlled Release Society. 2010; 146: 45-53. doi:10.1016/j.jconrel.2010.05.017.

149. Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H et al. Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther. 2013 Jul 18;7:571-83.